Compare RLJ & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLJ | ERAS |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2011 | 2021 |
| Metric | RLJ | ERAS |
|---|---|---|
| Price | $8.39 | $11.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $8.75 | $5.78 |
| AVG Volume (30 Days) | 1.6M | ★ 7.1M |
| Earning Date | 02-26-2026 | 03-19-2026 |
| Dividend Yield | ★ 7.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $1,351,163,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.36 | N/A |
| P/E Ratio | $188.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.16 | $1.01 |
| 52 Week High | $9.85 | $12.48 |
| Indicator | RLJ | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 68.99 | 73.97 |
| Support Level | $7.26 | $9.05 |
| Resistance Level | $7.92 | $12.48 |
| Average True Range (ATR) | 0.22 | 0.72 |
| MACD | 0.09 | -0.06 |
| Stochastic Oscillator | 98.70 | 73.91 |
RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.